On 28 February 2025, Biocon announced that it has launched its liraglutide products in the UK. The products are generic versions of Novo Nordisk’s Victoza®, to treat type 2 diabetes, and Saxenda®, used in the treatment of weight management. Biocon’s products are marketed under the brand names Liraglutide Biocon (gVictoza®) and Biolide (gSaxenda®).
Biocon’s liraglutide became the first UK-approved generic to Novo Nordisk’s liraglutide products in March 2024.
In December 2024, Biocon and its European partner, Zentiva, received approval for liraglutide in the European Union. The first EU-approved generic liraglutide was Adalvo’s liraglutide pre-filled pen in June 2024. Teva Pharmaceuticals launched the first authorised generic version of Victoza® in the US in June 2024.